Hypertrophic Cardiomyopathy (HCM) is a common disease of the heart muscles where the thickening of the myocardium results in functional impairment. HCM is a genetic condition affected by mutation in genes. As per the European Society of Cardiology, the occurrence of HCM in 2013 was between 0.05% and 0.2% of the population. According to a study presented by BioMed Central in 2010, there was no specific age and gender differences in the occurrence of HCM. The occurrence of HCM is reportedly the highest among African-Americans.
These factors have paved the way for the growth of the global hypertrophic cardiomyopathy therapeutics market. It is expected to register a steady CAGR of 1.40% between 2015 and 2023, states a new report published by Transparency Market Research. At this CAGR, the global hypertrophic cardiomyopathy therapeutics market is expected to reach US$1.4 bn by 2023.
TMR analysts answer some key questions that organizations in the global hypertrophic cardiomyopathy therapeutics market might ask:
Q. What are the drug classes of hypertrophic cardiomyopathy therapeutics and which one is expected to drive the global market?
To be precise, beta adrenergic blocking agents, calcium channel blockers, antiarrhythmic agents, anticoagulants, and others are some of the drug classes of HCM therapeutics. As per a recent study, over the past few years, the calcium channel blockers segment has been the dominant segment in terms of revenue. The calcium channel blockers segment is expected to progress at a 1.80% CAGR during the period from 2015 to 2023. This segment is expected to maintain its dominance in the years to come.
Q. What would drive and restrict the global hypertrophic cardiomyopathy therapeutics market in the near future?
A. The increasing occurrence of chronic cardiovascular diseases is expected to increase the demand for effective treatments in the years to come. This is expected to propel the global hypertrophic cardiomyopathy therapeutics market in the long run. The growing awareness about HCM across the developed countries is also expected to benefit the global hypertrophic cardiomyopathy therapeutics market in the near future. Even though the global market is set for rapid expansion, its growth is predicted to be affected by the rising technological improvement in equipment such as pacemakers and defibrillators. However, leading players are focusing on targeted therapy for hypertrophic cardiomyopathy, which is anticipated to benefit the global hypertrophic cardiomyopathy therapeutics market.
Q. Which diagnostic tools are used to evaluate hypertrophic cardiomyopathy therapeutics?
A. Over the past two decades, the pathogenic basis for HCM has been investigated broadly. Affecting roughly 1 in 500 people, HCM has become one of the common causes of sudden death, especially in young athletes. Patients with cardiomyopathy may complain of chest pain or may suffer heart failure. In some cases, HCM might be asymptomatic. Today, genomic medicines are changing the way HCM patients are treated. Continuous research and development into the discovery of new HCM susceptible genes and the increasing availability of genetic tests for HCM are changing the HCM therapeutics landscape rapidly.
Browse Research Release:
Following are some of the diagnostic tools, which are used for evaluating hypertrophic cardiomyopathy therapeutics (HCM):
- Cardiac magnetic resonance
- Doppler echocardiography
- 48-hour ambulatory ECG monitoring
- 24-hour ambulatory electrocardiographic monitoring
With governments of many nations offering a helping hand through funding, researchers are able to discover new HCM drugs. Thus, the global HCM therapeutics market is predicted to propel in the coming few years.